

Index

Note: page references in *italics* refer to tables

- Abraham, John 4–5, 54–66
Academy of Medical Sciences 7
Acomplia 46
Adams, Samuel Hopkins 15
advertising
 changes in drug advertising and implications for
 medicalisation 20–1, 20
 federal regulation and drug 15–16
 and patent medicines 12–14, 15
 see also DTCA (direct-to-consumer advertising)
Advertising Age 21
Advisory Committee on Immunization Practices
 (ACIP) 74, 75, 78
Agger, B. 37
AIDS
 in Brazil 85
Alliance for Cervical Cancer Prevention 76
Alzheimer's Society 119, 121
AMA (American Medical Association) 12, 15, 20
American Academy of Pediatrics 75
American College of Obstetricians and
 Gynecologists (ACOG) 74, 76
American Medical Association *see* AMA
Amyotrophic Lateral Sclerosis (ALS)
 (motor neurone disease) 147, 149
androgenic alopecia 49
anti-adulteration campaigns 58
antidepressants 8, 21, 126–38
 ambivalence towards by patients 134–5, 137
 increase in use of 126
 medical model of 133–4, 136
 problems with 126
 see also pharmacogenomics of depression
Antiretroviral Therapy (ART)
 distribution of in Brazil 5, 85
 see also Rio de Janeiro *favela*
Applbaum, M. 46
Arthritis Care 119, 121–2
aspirin 98
Association of the British Pharmaceutical Industry
 (ABPI) 113, 114, 115, 122–3
AstraZeneca 116, 116
attention-deficit hyperactivity disorder
 (ADHD) 49
 and Modafinil 29, 30
Avandia 74
Ayer, Dr James C. 13

Barr, Michael 8, 126–38
Barrett, A. 48

Bayer 47, 116
Belensky, Greg 33
benoxapofen 64
benzodiazepines
 media coverage 3, 25
Bernstein, M. 57
Biehl, J. 86
biological citizenship 5, 86
biomedicine 7
bioscience 7
biosociality 85
biotechnology 7
Bissell, P. 100
Blakemore, Colin 145
Blech, J. 2
Boden, Sharon 25–38
Boots Pharmaceutical 16
Bourdieu, Pierre 8, 140, 141–3, 144, 151–2
Brazil 5, 85
 AIDS cases 85
 distribution of antiretroviral therapy 5, 85
 see also Rio de Janeiro *favela*
Brazilian National Health System (SUS) 94
Brazilian National AIDS Programme (NAP) 85,
 90, 92, 94
breast cancer 48
British Medical Association 7
Brown, N. 129, 142
Bury, M. 25
Busfield, J. 4, 5

Cancerbackup 116, 118, 121
capital 141–2, 143, 151, 152
capitalism 37
capture theory 57, 58, 59
Carpenter, Laura M. 5, 71–81
Casper, Monica J. 5, 71–81
Cataldo, Fabian 5, 85–94
CDC (Centers for Disease Control) 73, 79
 Child and Adolescent Vaccination
 Schedule 75, 78
CEDAPS (Centre for Health Promotion) 87, 93
cell nuclear replacement (CNR) 148
Cephalon 26, 28, 31
Cervarix 71, 73, 81
cervical cancer 5, 72–3
 connection with HPV 73
 deaths caused by 72–3
 see also HPV vaccine
cervical intraepithelial neoplasia (CIN) 72

- Chernobyl disaster 86
- Childhood and Adolescent Immunization
Schedule 75, 78
- cholesterol-lowering drugs 42, 48
- Choosing Health through Pharmacy* 98
- Christian Right 77
- Cialis (tadalafil) 43, 45, 47
- Claritin 20
- clinical trials 5, 49
- Code of Practice 113
- cognitive behavioural therapy
and depression 136–7
- cognitive enhancement agents 7
- Colgrove, James 76, 81
- Colliers Weekly* 15
- Collins, H.M. 61, 62
- Collins, Thomas 17
- Committee on Safety of Drugs 58
- Committee on Safety of Medicines (CSM) 59
- Community Pharmacy Contract 98
- concordance 97
- Conrad, Peter 2, 12–22
- consumer groups *see* health consumer groups
- consumerism 6, 99–100, 109–10
- corporate bias
and drug regulation 4, 58–61
and drug safety 63–4
- corporatist theory
and drug regulation 57–8
- CYP2D6 126, 132
- daily life
pharmaceuticalisation of 4, 25–6, 37, 41, 45–8
- Daily Mail*
coverage of Modafinil 27, 28, 30, 31, 33
- Dangerous Drugs Act (1920) 59
- Davidson, Wayne 17
- Davis, Peter 1–9
- Department of Health 59, 147
- Department of Trade and Industry 7
- depression 8, 126–38
and cognitive behavioural therapy 136–7
increase in 126
medical model of 133–4, 136–7
pharmacogenomics of *see* pharmacogenomics of
depression
- diabetes
and cell stem research 144, 146
- direct-to-consumer advertising *see* DTCA
- disclosure issue
and consumer group-industry links 114–15,
117–18, 123, 124
- ‘disease in a dish’ approach
and stem cell research 8, 140, 141, 143, 147–51,
152
- disease-mongering 2, 25
- Ditka, Mike 19
- domestication of pharmaceutical consumption
3–4, 41, 42–5, 50
- drug adulteration 56
- drug disasters 56
- drug regulation 4–5, 54–62
bias of scientific knowledge-claims 61–2
and capture theory 57, 58, 59
and corporate bias 4, 58–61
and corporatist theory 57–8
fall in review times 60–1, 60
funding of regulatory agencies by drug
companies 59–60, 59
measures to counteract bias 4, 66
and neo-liberalism 57, 58
of patent medicines 15–16
and realist framework of interests 54, 56–7
streamlining global standards
and the ideology of pharmaceutical
innovation 64–6
- drug safety
international comparisons and the ideology
of 63–4
withdrawals 63
- drug testing 61–2, 64–6
- DTCA (direct-to-consumer advertising) 2, 12–22
campaign against patent drug 14–15
comparison with patent medicine advertising
12–14
emergence of prescription drug advertising and
regulation of 16–17
and erectile dysfunction 12, 18–19
impacts of on medicalisation and health 21
and Internet 21
and Lydia E. Pinkham’s Vegetable
Compound 2, 12, 13–14, 15–16, 19
scrutiny and criticism of 21
shift from prescription drugs to
over-the-counter 20
and television 18
- Duggan, Catherine 6, 97–110
- ‘e-clinics’ 43
- Elixir Sulfanilimide drug disaster (1937) 58
- ENUSP (European Network of (ex) Users and
Survivors of Psychiatry) 134
- erectile dysfunction (ED) 2, 44, 50
and DTCA 12, 18–19
see also Viagra
- Escitalopram 127
- ESRC 114, 115
- ethical capital 141, 142
- ethical drug manufacturers 20
- ethical pharmaceuticals 56
- European Medicines Evaluation Agency
(EMA) 6
percentage of industry fee contribution to
budget 59, 59
- excessive sleepiness 26, 29, 30
- expectational capital 142, 143, 144, 146, 149, 151,
152
- expert patient, notion of 99

- Fairhurst, K. 99
 Family Research Council (FRC) 79
 Farmer, P. 94
 'fast' capitalism 37
favela see Rio de Janeiro *favela*
 FDA (Food and Drugs Administration) 71
 budgetary cuts 60
 and drug safety 63–4
 and DTCA 16, 17, 18, 22
 and HPA vaccine 74
 and Modafinil 26
 percentage of industry fee contribution to
 spending on drug review 59, 59
 regulatory review times 60–1, 60
 trends in drug and biological product
 submissions 65
 and Viagra 19
 Feldman, A. 88
 female sexual dysfunction (FSD) 46, 49
 fields 141, 142, 151
 finasteride 42
 Fishman, J.R. 46, 48–9
 Flower, R. 42, 50
 Focus on the Family (FOF) 79
 Food and Drug Act (1906) 20
 Fox, Nick J. 3, 41–50
 Freedom of Information Act 79
 Frist, Bill 21

 Gabe, Jonathan 1–9, 25
 Gardasil 71, 73–4, 75, 78
 GENDEP (genome-based therapies for
 depression) 8, 126–7, 129
 gender
 and HPV vaccine 5, 71–81
 and sexual activity 77–8
 genetic engineering approach
 and stem cell research 148–9, 150, 151
 genome-based therapies for depression see
 GENDEP
 Germany
 view of pharmacogenomics of
 depression 130
 Gill, O.N. 75
 GlaxoSmithKline see GSK
 Greener, I. 99
 Grime, J. 134
 Grupo Pela Vidda Rio (GPV) 87, 93
 GSK (GlaxoSmithKline) 47, 80
 and Cervarix 71, 74, 81
 support for consumer groups 116, 116
Guardian
 coverage of Modafinil 27, 28, 33–4, 35

 habitus 141, 151
 Harding, G. 98
 Harris, O. 88
 Hayek, F. 55
 Hayes, Arthur Hull 16

 health care
 public participation in 16–17, 97–8, 99
 health consumer groups
 availability of drugs issue 123
 conditions receiving support from
 companies 117
 disclosure over links issue 113, 114–15,
 117–18, 123, 124
 ethical issues 120–2
 funding 116–17, 124
 policy guidelines 119–20, 122
 rationale for links 118
 relationship with pharmaceutical industry
 6, 112–24
 research methodology 114
 support of groups by industry 115–17, 116,
 117, 123–4
 types of support 116
 view of by other policy actors 122–3
Health on the Net Foundation's 'HonCode' 119
 Hedgecoe, A. 136
 Henwood, F. 97
 Hepatitis B
 vaccine against 81
 herceptin 48, 132, 136
 hES (human embryonic stem) cell research see
 stem cell research
 HFEA 148
 Hibbert, D. 100, 109
 Hinojosa, Cantu 79
 HIV
 distribution of antiretroviral therapy
 in Brazil 5, 85
 see also Rio de Janeiro *favela*
 Holloway, Thomas 13
 House of Commons Health Committee
 The Influence of the Pharmaceutical Industry
 report (2005) 4, 122
 HPV (human papillomavirus) 73
 HPV vaccine 5, 71–81
 and cervical cancer screening 75–6
 described 73
 forging of new health-care markets 75
 and mandatory vaccination issue 76–7, 80
 opposition to by practitioners 75
 parental attitude 80
 and patient-provider relations 74–5
 predicted sales 74
 and sexual politics 77–80
 and strategies of containment 71–2
 target population 73
 see also Cervarix; Gardasil
 Huntingdon's disease 149, 150
 Hurst, S.A. 113
 Hwang, Professor 148

 Illich, I. 1
 impotence see erectile dysfunction
Independent

- coverage of Modafinil 27, 28, 29, 32
- inequalities
 - in drug provision 5
- interests
 - realist framework of 55–7
- International Association of Athletics Federation (IAAF) 34, 35
- International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) 64–6
- International Federation of Pharmaceutical Manufacturers' Associations (IFPMA) 64
- Internet 25, 41, 42, 46
 - availability of drugs on 3, 32, 45
 - and DTCA 21
 - and online consultation 43
 - and Viagra 43, 44, 45
- Jacob, M. 75
- Jenkins, Ian 34
- Joint Committee on Prescribing 59
- Jones, Kathryn 6, 112–24
- Judicial Watch 79
- Karp, D. 135
- Kramer, P. 133
- Kravitz, R.L. 21
- Kroll-Smith, S. 36
- Ladies Home Journal* 15
- Laube, Douglas W. 74
- Leiter, Valerie 2, 12–22
- Leontowitsch, Miranda 6, 97–110
- Levitra (vardenafil) 2, 19, 20, 47
- Lexchin, J. 42, 49
- Lexis Nexis archival database 27
- licensing process 4, 63
- life-cycle theory 57
- lifestyle drugs 32, 42
 - contribution to drug company profits 46
 - Modafinil as 27, 28–31, 28, 36
 - Viagra as 41, 42, 46–7, 48
- lifestyle marketing 41
- Lilly and Co 116, 126
- 'Limited List' 59
- Lofgren, H. 112
- Long-term Medical Conditions Alliance (LTCA) 119
- Lowe, Pam 25–38
- Lowndes, C.M. 75
- Lupton, D. 99, 106, 109
- Lydia E. Pinkham's Vegetable Compound 2, 12, 13–14, 15–16, 19
- Makland, Dr Colin 28
- Marshall, B.L. 46, 49
- Mauron, A. 113
- May, C. 99
- Mays, R.M. 75
- media 1, 3, 25–6
 - see also newspapers
- Medical Research Council see MRC
- medicalisation of life 22
 - and direct-to-consumer advertising 12–22
 - role of pharmaceuticals in 1–4
- Medicines Act (1968) 58
- Medicines and Healthcare Products Regulatory Agency (MHRA) 4, 26, 66
- Mental Health Foundation 136
- Merck 71, 73, 74, 79, 80, 81
- methadone 42
- methylphenidate (Ritalin) 49
- Michael, Mike 140–53
- military
 - newspaper coverage of Modafinil and 33–4
- Ministry of Health 58
- minoxidil 42
- Mirror* 28
- Modafinil (Provigil) 25–38
 - press coverage 3, 27–38, 28
 - competition theme 27, 28, 34–5, 36
 - lifestyle choices theme 27, 28, 31–3, 36
 - medical use theme 27, 28–31, 28, 36
 - military uses of 27, 28, 33–4, 36
- Moran, M. 112, 123
- Morros dos Reis *favela* (Rio de Janeiro) 88, 89–93
- Mortimer, John 30–1
- motor neurone disease 147
- Moynihan, R. 2
- MRC (Medical Research Council) 145, 146, 147
- narcolepsy 28–9
- Nathanson, C.A. 80
- National Health Service (NHS)
 - medicine costs 1
- National Heart Forum (NHF) 115
- National Institute for Health and Clinical Excellence (NICE) 48, 113, 121, 136–7
- National Institutes of Health (NIH) 145
- National Organization for Women (NOW) 78, 79
- National Pharmaceutical Association (NPA) 98
- National Poll on Children's Health 80
- Nazeer, S. 76
- Nelkin, D. 25
- neo-liberal corporate bias 54, 58, 59–66
- neo-liberalism
 - and drug regulation 57, 58
- neuroscience, developments in 7
- New and Nonofficial Remedies* 15
- new social movements 112
- Newman, Paul 47
- Newman, R. 47, 49
- News of the World* 29
- Newspaper Marketing Agency 27
- newspapers
 - coverage of Modafinil see Modafinil
 - and patent medicine advertising 13
 - retrieving and analysing stories from 27

- Nguyen, V. 85, 86
 NMEs (new molecular entities) 66
 cost of bringing to the market 64
 decline in 66
 FDA review and approval times 60, 60
 numbers first launched onto world market 65, 66
 norethisterone 42
 Nortripyline 127
 Novas, C. 86, 137
 Nuffield Report (1986) 98
- obesity 44
 obstructive sleep apnoea (OSA) 26, 29
 orlistat *see* Xenical
 Ormrod, S. 42
 over-the-counter (OTC) medicines
 and pharmacist-customer relationship
 see pharmacist-customer discourses
- paroxetine (Seroxat or Paxil) 49
 participation in health care 16–17, 97–8, 99
 participatory practice model 103–5
 patent medicines 12–13, 19, 58
 and advertising 12–14, 15
 campaigns against 14–15
 regulation of 15–16
 Pattison Report (2005) 145, 147
 Penglase, B. 88–9
 ‘personalised’ medicine 7–8
 Petryna, A. 85, 86
 Pfizer 19, 41, 46, 47, 49, 116, 116
 PGD embryos
 use of in stem cell research 149–50, 151
 Pharmaceutical Advertising Council 16
 pharmaceutical companies 1, 2
 biomedicalisation of lifestyle conditions 49
 funding of regulatory agencies 59–60, 59
 marketing strategies and target audiences 47–8
 profits 45–6
 relations with health consumer groups *see*
 healthy consumer groups
 working with patient groups 48
 see also drug regulation
 pharmaceutical consumption
 domestication of 3–4, 41, 42–5, 50
 pharmaceuticalisation 3
 of daily life 4, 37, 25–6, 41, 45–50
 pharmaceuticals
 role in medicalisation of society 1–4
 sales 1
 pharmacist-customer discourses 6, 97–110
 and consumerism 99–100
 participatory practice model 103–5, 109, 110
 research methods 100–2, 101
 role of professional expertise 105–7, 109
 view of consumer discourses by
 pharmacists 107–9
 pharmacists 6
 role and professional status of 98–9
- pharmacogenetics 7–8
 pharmacogenomics of depression 7, 126–38
 ambivalence regarding use of
 antidepressants 134–5, 137
 conflation between drug reactions and disease
 risks 132–3, 136
 criticism of medial model of depression 133–4,
 136–7
 differences between psychiatric and physical
 illness 135–6, 137
 research methodology 127–9
 views on 130–1
 ‘pharmacological Calvinism’ 38
Pharmacy in the Future 97
 Pharmacy and Medicines Act (1941) 58
 phentermine (Adipex or ‘phen’) 43, 47
 Pines, W.L. 16, 17
 ‘pink Viagra’ 49
 Pinkham, Lydia 2, 12, 13–14, 15–16, 19
 Planned Parenthood Federation of America
 (PPFA) 78, 79
- Poland
 view of pharmacogenomics of depression 130
 political sociology
 and drug regulation 57–61
 politicisation 7
 politics 71–2
 Pollitt, Katha 79
 Pollock, K. 134
 Potts, A. 50
 Prescription Drug Users Fee Act (PDUFA)
 (1992) 60
 Proprietary Association of America 15
 Protestant work ethic 38
 Provigil *see* Modafinil
 Prozac 25, 126
 psychiatric illness 8
 psychopharmaceuticals 7
Public Library of Science – Medicine 2
 Pure Food and Drug Act (1906) 15
- Rainbow, P. 143–4
 Raley, J.C. 74
 regulation *see* drug regulation
 regulatory agencies 64
 fall in review times 60–1, 60
 funding of 59–60, 59, 66
 ‘life-cycle’ theory of 57
 relativist-constructivists 61–2, 66
 reproductive health technologies 71
 review times, regulatory 60–1, 60
 rimonabant (Acomplia) 46
 Rio de Janeiro *favela* 5, 85–94
 creation of therapeutic networks by distribution
 of ART 93, 94
 dependency on government through ART 92
 drug trafficking 88–9
 encouragement of new biosocialities through
 ART 90–2, 94

- and NGOs 93
- political alienation and renewed marginalisation 87–9, 92
- research methods on 86–7
- taking ART into 89–92
- Ritalin (methylphenidate) 49
- Roche 46
- rofecoxib 121
- Rose, Diana 7, 8, 126–38
- Rose, N. 86
- Royal Society 131, 132

- Sawaya, G.F. 75
- Schwarz, M. 55
- science
 - and relativist-constructivists 61–2
 - science and technology studies (STS) 140
 - scientific capital 141–2, 144, 149, 150, 151
 - Seale, Clive 25–38
 - self-diagnosis 16–17, 22
 - Service User Research Enterprise (SURE) 128
 - sex education policy 77
 - sexual politics
 - and HPV vaccine 77–80
 - sexuality/sexual activity 45, 77–8
 - pharmaceuticalisation of 46–7
 - sexually transmitted infections *see* STIs
 - shift work sleep disorder 26, 29
 - sildenafil *see* Viagra
 - Sinclair, Upton
 - The Jungle* 15
 - Smith Kline & French Laboratories 17
 - Smith-McCune, K. 75
 - social phobia 49
 - Society for Adolescent Medicine (SAM) 74
 - sociology of expectations 7, 140, 142–3, 151, 152
 - sociology of scientific knowledge (SSK) 61, 62
 - somatic cell nuclear transfer (SCNT) 148
 - squamous intraepithelial lesion (SIL) 72
 - Steinberg, Deborah Lynn 25–38
 - stem cell research 8, 140–53
 - and Bourdieu 141–3, 151–2
 - and ‘disease in a dish’ approach 8, 140, 141, 143, 147–51, 152
 - expectations characterising 146–7
 - genetic engineering approach 148–9, 150, 151
 - problem of ‘premature publication’ 144
 - and scepticism 152–3
 - and therapeutic cloning 148, 151
 - transplantation versus Pharma 143–7, 151
 - use of affected PGD embryos 149–50, 151
 - Stevenson, Fiona A. 6, 97–110
 - STIs (sexually transmitted infections) 5, 73, 75, 77, 80
 - Stroke Association 116, 118
 - Sun*
 - coverage of Modafinil 28, 35
 - Sunday Times* 31
 - supermarket model of consumerism 99, 110

 - Tacrine 136
 - tadalafil *see* Cialis
 - Taylor, K. 98
 - technology 42
 - television
 - and DTCA 18
 - thalidomide 58
 - therapeutic citizenship 5, 86, 94
 - therapeutic cloning 148, 151
 - Thompson, M. 55
 - Times*
 - coverage of Modafinil 27, 28, 29, 31, 32, 34–5
 - translational research 140

 - vaccination/vaccines 5, 80
 - development of new 7
 - mandatory school debate 76
 - politicised nature of in US 76
 - see also* HPV vaccine
 - Van der Geest, S. 71–2
 - vardenafil *see* Levitra
 - Viagra (sildenafil) 31, 36, 43, 49, 50
 - advertising of 19
 - history of 18–19
 - and Internet 43, 44, 45
 - as lifestyle drug 41, 42, 46–7, 48
 - and media 25
 - negative consequences of 50
 - pink 49
 - sales 46
 - Vioxx 21, 74

 - Wainwright, Steven P. 8, 140–53
 - Ward, Kate J. 3, 41–50
 - weight loss 43, 45
 - and online consultation 43–4
 - pharmaceuticalisation of 47
 - weight loss pharmaceuticals 42, 45, 46, 47, 50
 - see also* Xenical (orlistat)
 - Which?* 119
 - White, Kelli 34–5
 - Williams, Clare 140–53
 - Williams, Simon J. 1–9, 25–38
 - Women in Government 74
 - Woodcock, Janet 22
 - Woolgar, S. 55
 - World Anti-Doping Agency (WADA) 35
 - World Health Organization 72, 126
 - Wright Mills, C. 9

 - Xenical (orlistat) 41, 42, 43–4, 45, 46, 47, 48

 - Yearley, S. 61, 62

 - Zimet, G.D. 75